APTrans signs agreement with Evgen Pharma to support the development of the lead product, SFX-01.  

In February, APTrans signed a service agreement with Evgen Pharma to provide support to their lead program, SFX-01. Evgen Pharma is a clinical stage drug development company with projects in breast cancer and subarachnoid haemorrhage. APTrans is a consortium of companies based at the BioHub at Alderley Park, formed by ApconiX, Aptus Clinical and Seda [...]

By |2018-07-11T16:56:25+00:00March 8th, 2017|Press|Comments Off on APTrans signs agreement with Evgen Pharma to support the development of the lead product, SFX-01.